LIAISON Biotrin Parvovirus B19 IgG Plus and Control

The LIAISON Biotrin Parvovirus B19 IgG Plus is designed to analyze human serum, as well as plasma collected with lithium heparin, dipotassium EDTA (K2-EDTA), or sodium citrate. This flexibility is important because it allows clinicians to use samples that are commonly collected for routine testing, reducing the need for additional phlebotomy or special handling. The test is specifically intended for qualitative detection of IgG antibodies to parvovirus B19, which helps in diagnosing fifth disease (erythema infectiosum) and assessing exposure risk in women of childbearing age.

Yes, the LIAISON Biotrin Parvovirus B19 IgG Plus is **exclusively** designed to be performed on the LIAISON XL Analyzer. This means the test cannot be used on other immunoassay platforms, and laboratories must have this specific analyzer to run it. The analyzer’s compatibility ensures consistent results and proper calibration, which is critical for accurate diagnosis of parvovirus B19 exposure or fifth disease.

The paired control serves as a quality assurance measure to verify the performance of the LIAISON Biotrin Parvovirus B19 IgG Plus assay before running patient samples. It helps ensure the test is functioning correctly, reducing the risk of false positives or negatives due to equipment malfunctions, reagent degradation, or procedural errors. This is particularly important in clinical settings where accurate results directly impact patient management, such as in diagnosing parvovirus B19 infections or assessing maternal-fetal risks.

The device follows standard immunoassay storage and handling protocols, meaning it should be stored according to the manufacturer’s instructions provided with the kit (typically refrigerated or at room temperature, depending on the specific lot). No additional sterility or MRI safety considerations apply, as it is intended for laboratory use only and is not implanted or exposed to magnetic fields. Proper storage ensures the assay’s reagents remain stable and reliable for accurate testing.

The assay is intended for **qualitative detection of IgG antibodies** to parvovirus B19 in patients, aiding in diagnosing fifth disease (erythema infectiosum) and assessing exposure risk—especially in women of childbearing age. This is clinically relevant because parvovirus B19 infections during pregnancy can pose risks to fetal health, such as hydrops fetalis or miscarriage. The test helps clinicians identify prior exposure (via IgG presence) or active infection (via IgM, if available), guiding preventive or supportive care decisions.